- Home
- ACRS vs EDIT Comparison
ACRS vs EDIT Comparison
Compare ACRS & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- EDIT
- Stock Information
- Founded
- ACRS 2012
- EDIT 2013
- Country
- ACRS United States
- EDIT United States
- Employees
- ACRS N/A
- EDIT N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACRS Health Care
- EDIT Health Care
- Exchange
- ACRS Nasdaq
- EDIT Nasdaq
- Market Cap
- ACRS 165.7M
- EDIT 156.5M
- IPO Year
- ACRS 2015
- EDIT 2016
- Fundamental
- Price
- ACRS $1.45
- EDIT $2.25
- Analyst Decision
- ACRS Strong Buy
- EDIT Buy
- Analyst Count
- ACRS 8
- EDIT 13
- Target Price
- ACRS $9.71
- EDIT $6.73
- AVG Volume (30 Days)
- ACRS 755.2K
- EDIT 2.4M
- Earning Date
- ACRS 08-06-2025
- EDIT 08-06-2025
- Dividend Yield
- ACRS N/A
- EDIT N/A
- EPS Growth
- ACRS N/A
- EDIT N/A
- EPS
- ACRS N/A
- EDIT N/A
- Revenue
- ACRS $17,777,000.00
- EDIT $35,837,000.00
- Revenue This Year
- ACRS N/A
- EDIT N/A
- Revenue Next Year
- ACRS $11.77
- EDIT N/A
- P/E Ratio
- ACRS N/A
- EDIT N/A
- Revenue Growth
- ACRS N/A
- EDIT N/A
- 52 Week Low
- ACRS $1.05
- EDIT $0.91
- 52 Week High
- ACRS $5.17
- EDIT $6.05
- Technical
- Relative Strength Index (RSI)
- ACRS 51.96
- EDIT 63.76
- Support Level
- ACRS $1.37
- EDIT $2.05
- Resistance Level
- ACRS $1.59
- EDIT $2.55
- Average True Range (ATR)
- ACRS 0.10
- EDIT 0.23
- MACD
- ACRS -0.01
- EDIT 0.03
- Stochastic Oscillator
- ACRS 28.57
- EDIT 66.29
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.